SCHEMBL26740596

SCHEMBL26740596

Cc1ccc(COC(=O)c2cccc(=O)n2C)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.53
MMP12 P39900 2/20 0.53
MMP1 P03956 2/20 0.53
MMP9 P14780 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
KMT2A Q03164 1/20 0.50
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
L3MBTL1 Q9Y468 3/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
NPY1R P25929 1/20 0.43
MAOB P27338 1/20 0.43
ADORA2A P29274 1/20 0.43
RECQL P46063 1/20 0.43
NPY2R P49146 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22959441 0.87 NPC1 (0.47) MMP2MMP12MMP1MMP9SMN1; SMN2
SCHEMBL30636845 0.87 NPC1 (0.47) MMP2MMP12MMP1MMP9SMN1; SMN2
SCHEMBL1839413 0.82 CA12 (0.49) SMN1; SMN2MEN1LMNAKMT2ANPC1
SCHEMBL2404923 0.76 ALDH1A1 (0.50) MMP12MMP1MMP9LMNAL3MBTL1
SCHEMBL6653627 0.72 L3MBTL1 (0.61) MMP2MMP12MMP1MMP9MEN1
SCHEMBL22005648 0.72 TDP1 (0.53) SMN1; SMN2LMNAKMT2ANPC1RAB9A
SCHEMBL1837909 0.71 ALDH1A1 (0.55) MMP2MMP12MMP1MMP9LMNA
SCHEMBL6653763 0.71 KMT2A (0.71) MMP2MMP12MMP1MMP9SMN1; SMN2
SCHEMBL13932521 0.71 KMT2A (0.71) MMP2MMP12MMP1MMP9SMN1; SMN2
SCHEMBL2354687 0.70 KMT2A (0.76) MMP2MMP12MMP1MMP9MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357154-A1 BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM TREVENTIS CORPORATION (US) 2023-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357154-A1 BUTYRYLCHOLINESTERASE COMPOUNDS AND USE IN DISEASES OF THE NERVOUS SYSTEM BCHE, ACHE, CHAT MMP2 345/4885MMP12 1602/4885MMP1 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.